NKNynke M. Kannegieter

Nynke M. Kannegieter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nynke M. Kannegieter has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Carla C. Baan

    Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; and

    6 shared publications
  • Marjolein Dieterich

    Department of Internal Medicine, Section of Transplantation and Nephrology, Rotterdam Transplant Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

    4 shared publications
  • Rens Kraaijeveld

    Department of Internal Medicine, Section of Transplantation and Nephrology, Rotterdam Transplant Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

    4 shared publications
  • Dennis A. Hesselink

    Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    3 shared publications
  • Dennis A Hesselink

    Department of Internal Medicine, Section of Transplantation and Nephrology, Rotterdam Transplant Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

    2 shared publications
  • Ajda T Rowshani

    Department of Internal Medicine, Section of Transplantation and Nephrology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients

    by Nynke M Kannegieter, Dennis A Hesselink, Marjolein Dieterich, Gretchen N de Graav, Rens Kraaijeveld, Carla C Baan

    Therapeutic drug monitoring (TDM) of tacrolimus, based on blood concentrations, shows an imperfect correlation with the occurrence of rejection. Here, we tested whether measuring NFATc1 amplification, a member of the calcineurin pathway, is suitable for TDM of tacrolimus. NFATc1 amplification was monitored in T cells of kidney transplant recipients who received either tacrolimus- (n = 11) or belatacept-based (n = 10) therapy. Individual drug effects on NFATc1 amplification were studied in vitro, after spiking blood samples of healthy volunteers with either tacrolimus, belatacept or mycophenolate mofetil. At day 30 after transplantation, in tacrolimus-treated patients, NFATc1 amplification was inhibited in CD4+ T cells expressing the co-stimulation receptor CD28 (mean inhibition 37%; p = 0.01) and in CD8+CD28+ T cells (29% inhibition; p = 0.02), while this was not observed in CD8+CD28- T cells or belatacept-treated patients. Tacrolimus pre-dose concentrations of these patients correlated inversely with NFATc1 amplification in CD28+ T cells (rs = -0.46; p < 0.01). In vitro experiments revealed that 50 ng/ml tacrolimus affected NFATc1 amplification by 58% (mean; p = 0.02). In conclusion, measuring NFATc1 amplification is a direct tool for monitoring biological effects of tacrolimus on T cells in whole blood samples of kidney transplant recipients. This technique has potential that requires further development before it can be applied in daily practice.


  • Open Access

    Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial

    by Nynke M. Kannegieter, Dennis A. Hesselink, Marjolein Dieterich, Gretchen N. de Graav, Rens Kraaijeveld, Carla C. Baan

    Pharmacokinetic immunosuppressive drug monitoring poorly correlates with clinical outcomes after solid organ transplantation. A promising method for pharmacodynamic monitoring of tacrolimus (TAC) in T cell subsets of transplant recipients might be the measurement of (phosphorylated) p38MAPK, ERK1/2 and Akt (activated downstream of the T cell receptor) by phospho-specific flow cytometry. Here, blood samples from n = 40 kidney transplant recipients (treated with either TAC-based or belatacept (BELA)-based immunosuppressive drug therapy) were monitored before and throughout the first year after transplantation. After transplantation and in unstimulated samples, p-p38MAPK and p-Akt were inhibited in CD8+ T cells and p-ERK in CD4+ T cells but only in patients who received TAC-based therapy. After activation with PMA/ionomycin, p-p38MAPK and p-AKT were significantly inhibited in CD4+ and CD8+ T cells when TAC was given, compared to pre-transplantation. Eleven BELA-treated patients had a biopsy-proven acute rejection, which was associated with higher p-ERK levels in both CD4+ and CD8+ T cells compared to patients without rejection. In conclusion, phospho-specific flow cytometry is a promising tool to pharmacodynamically monitor TAC-based therapy. In contrast to TAC-based therapy, BELA-based immunosuppression does not inhibit key T cell activation pathways which may contribute to the high rejection incidence among BELA-treated transplant recipients.


  • Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation

    by Nynke M. Kannegieter, Dennis A. Hesselink, Marjolein Dieterich, Gretchen N. de Graav, Rens Kraaijeveld, Ajda T. Rowshani, Pieter J. M. Leenen, Carla C. Baan

    Monocytes significantly contribute to ischemia reperfusion injury and allograft rejection after kidney transplantation. However, the knowledge about the effects of immunosuppressive drugs on monocyte activation is limited. Conventional pharmacokinetic methods for immunosuppressive drug monitoring are not cell type-specific. In this study, phosphorylation of three signaling proteins was measured to determine the pharmacodynamic effects of immunosuppression on monocyte activation in kidney transplant patients. Blood samples from 20 kidney transplant recipients were monitored before and during the first year after transplantation. All patients received induction therapy with basiliximab, followed by tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisolone maintenance therapy. TAC whole-blood pre-dose concentrations were determined using an antibody-conjugated magnetic immunoassay. Samples were stimulated with PMA/ionomycin and phosphorylation of p38MAPK, ERK, and Akt in CD14+ monocytes was quantified by phospho-specific flow cytometry. Phosphorylation of p38MAPK and Akt in monocytes of immunosuppressed recipients was lower after 360 days compared with before transplantation in the unstimulated samples (mean median fluorescence intensity (MFI) reduction 36%; range -28% to 77% for p-p38MAPK and 20%; range -22% to 53% for p-Akt; p < 0.05). P-ERK was only decreased at day 4 after transplantation (mean inhibition 23%; range -52% to 73%; p < 0.05). At day 4, when the highest whole-blood pre-dose TAC concentrations were measured, p-p38MAPK and p-Akt, but not p-ERK, correlated inversely with TAC (rs = -0.65; p = 0.01 and rs = -0.58; p = 0.03, respectively). Immunosuppressive drug combination therapy partially inhibits monocyte activation pathways after kidney transplantation. This inhibition can be determined by phospho-specific flow cytometry, which enables the assessment of the pharmacodynamic effects of immunosuppressive drugs in a cell-type-specific manner.


  • Open Access

    pERK-dependent defective TCR-mediated activation of CD4+ T cells in end-stage renal disease patients

    by Ling Huang, Nicolle H. R. Litjens, Nynke M. Kannegieter, Mariska Klepper, Carla C. Baan, Michiel G. H. Betjes

    Patients with end-stage renal disease (ESRD) have an impaired immune response with a prematurely aged T-cell system. Mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated kinase (ERK) and p38, regulate diverse cellular programs by transferring extracellular signals into an intracellular response. T cell receptor (TCR)-induced phosphorylation of ERK (pERK) may show an age-associated decline, which can be reversed by inhibiting dual specific phosphatase (DUSP) 6, a cytoplasmic phosphatase with substrate specificity to dephosphorylate pERK. The aim of this study was to assess whether ESRD affects TCR-mediated signaling and explore possibilities for intervening in ESRD-associated defective T-cell mediated immunity. An age-associated decline in TCR-induced pERK-levels was observed in the different CD4+ (P < 0.05), but not CD8+, T-cell subsets from healthy individuals (HI). Interestingly, pERK-levels of CD4+ T-cell subsets from young ESRD patients were in between young and elderly HI. A differentiation-associated decline in TCR-induced ERK and p38 phosphorylation was observed in T cells, although TCR-induced p38 phosphorylation was not significantly affected by age and/or ESRD. Frequencies of TCR-induced CD69-expressing CD4+ T cells declined with age and were positively associated with pERK. In addition, an age-associated tendency of increased expression of DUSP6 was observed in CD4+ T cells of HI and DUSP6 expression in young ESRD patients was similar to old HI. Inhibition of DUSP6 significantly increased TCR-induced pERK-levels of CD4+ T cells in young and elderly ESRD patients, and elderly HI. TCR-mediated phosphorylation of ERK is affected in young ESRD patients consistent with the concept of premature immunological T cell ageing. Inhibition of DUSP6 specific for pERK might be a potential intervention enhancing T-cell mediated immunity in ESRD patients.


  • Open Access

    The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function

    by Nynke M Kannegieter, Dennis A Hesselink, Marjolein Dieterich, Rens Kraaijeveld, Ajda T Rowshani, Pieter J M Leenen, Carla C Baan

    Monocytes and macrophages play key roles in many disease states, including cellular and humoral rejection after solid organ transplantation (SOT). To suppress alloimmunity after SOT, immunosuppressive drug therapy is necessary. However, little is known about the effects of the immunosuppressive drugs tacrolimus and mycophenolic acid (MPA) on monocyte activation and function. Here, the effect of these immunosuppressants on monocytes was investigated by measuring phosphorylation of three intracellular signaling proteins which all have a major role in monocyte function: p38MAPK, ERK and Akt. In addition, biological functions downstream of these signaling pathways were studied, including cytokine production, phagocytosis and differentiation into macrophages. To this end, blood samples from healthy volunteers were spiked with diverse concentrations of tacrolimus and MPA. Tacrolimus (200 ng/ml) inhibited phosphorylation of p38MAPK by 30% (mean) in CD14+ monocytes which was significantly less than in activated CD3+ T cells (max 60%; p < 0.05). This immunosuppressive agent also partly inhibited p-AKT (14%). MPA, at a therapeutic concentration showed the strongest effect on p-AKT (27% inhibition). p-ERK was inhibited with a maximum of 15% after spiking with either tacrolimus or MPA. The production of IL-1β and phagocytosis by monocytes were not affected by tacrolimus concentrations, whereas MPA did inhibit IL-1β production by 50%. Monocyte/macrophage polarization was shifted to an M2-like phenotype in the presence of tacrolimus, while MPA increased the expression of M2 surface markers, including CD163 and CD200R, on M1 macrophages. These results show that tacrolimus and MPA do not strongly affect monocyte function, apart from a change in macrophage polarization, to a clinically relevant degree.


  • Conversion to Once-Daily Tacrolimus Results in Increased p38MAPK Phosphorylation in T Lymphocytes of Kidney Transplant Recipients

    by Nynke M. Kannegieter, Nauras Shuker, Ramin Vafadari, Willem Weimar, Dennis A. Hesselink, Carla C. Baan

    The once-daily formulation of tacrolimus (TACOD) has been developed to overcome adherence problems. Conversion from the twice-daily TAC (TACBID) formulation to TACOD on a 1:1 basis, however, often leads to a decrease of TAC pre-dose concentrations which averages ∼15%. Switching between the two TAC formulations may thus influence drug efficacy and necessitates therapeutic drug monitoring. As an additional tool in transplantation diagnostics, phospho-specific flow cytometry was used to study the biological effects of conversion on p38MAPK phosphorylation, a kinase involved in T-lymphocyte activation.Stable renal transplant recipients (n=12), at least one year after their transplantation, were converted from TACBID to TACOD on 1:1 mg for mg base. Co-medication consisted of mycophenolate mofetil (n=10) and prednisolone (n=3). TAC whole-blood pre-dose concentrations were determined by immunoassay before and 3 months after conversion. P38MAPK phosphorylation was measured in T-lymphocytes by whole-blood phospho-specific flow cytometry.Three months after conversion, no significant decreases in TAC pre-dose concentrations (C0) were found (p = 0.54), while p38MAPK phosphorylation increased with 11.4% (p<0.05) in CD4+ and with 15.6% (p<0.05) in CD8+ T-lymphocytes. The TAC C0 during treatment with TACBID correlated inversely with p38MAPK phosphorylation in T-lymphocytes (rs= -0.638, p <0.05).These results suggest that measurement of p38MAPK phosphorylation status in T-lymphocytes is a sensitive method to determine the biological effects of TAC before and after conversion from TACBID to TACOD. This method could be a more sensitive tool for therapeutic drug monitoring of TAC.